Reticulocyte Parameters as Early Indicators of Bone Marrow Erythropoietic Activity in Chronic B Lymphoproliferative Neoplasms
NCT07337967 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 120
Last updated 2026-01-13
Summary
Reticulocyte parameters as early indicators of bone marrow erythropoietic activity in chronic B lymphoproliferative neoplasms
Conditions
- B Chronic Lymphocytic Leukemia
Sponsors & Collaborators
-
Huda Ahmed Abdelsabour Abdelwahab
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2026-01-01
- Primary Completion
- 2027-02-01
- Completion
- 2027-09-01
More Related Trials
-
Cancer and Immune Cell Metabolism in Patients With Hematological Malignancies
NCT07189117 ·Status: RECRUITING
-
Biomarkers in Bone Marrow Samples From Patients With Acute Myeloid Leukemia
NCT01251159 ·Status: COMPLETED
-
Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia
NCT03367299 ·Status: COMPLETED ·Phase: PHASE2
-
Studying Biomarkers in Cell Samples From Patients With Acute Myeloid Leukemia
NCT01057199 ·Status: COMPLETED
-
Studying Biomarkers in Samples From Younger Patients With Acute Myeloid Leukemia
NCT01642121 ·Status: COMPLETED
-
Study of Bone Marrow Samples From Patients With Acute Leukemia
NCT00897559 ·Status: COMPLETED
-
Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
NCT02437019 ·Status: APPROVED_FOR_MARKETING
-
Immunophenotypic Evaluation of IL-7R α in Acute Leukaemia
NCT05643547 ·Status: UNKNOWN
-
New Markers for Minimal Residual Disease in Acute Lymphoblastic Leukemia
NCT03249636 ·Status: UNKNOWN
-
Role of Cbc Indices in Acute Lymphoblastic Leukemia Patients
NCT06746571 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
NCT01463046 ·Status: COMPLETED ·Phase: PHASE1
-
Biomarker Study in Tissue Samples From Patients With Acute Myeloid Leukemia
NCT01232842 ·Status: COMPLETED
-
Laboratory Studies Into the Pathology of Leukaemia
NCT03233763 ·Status: UNKNOWN
-
Genotyping Analysis of Acute Lymphoblastic Leukemia
NCT00961285 ·Status: UNKNOWN
-
Unravelling the Role of KCTD Protein Family in the Clinical Management of Childhood Acute Lymphoblastic Leukemias
NCT05729178 ·Status: RECRUITING
-
Biomarker Study in Bone Marrow Samples From Patients With T-Cell Acute Lymphoblastic Leukemia
NCT01295476 ·Status: COMPLETED
-
Study of Proteins in Promoting Chemotherapy Resistance in Samples From Patients With Acute Myeloid Leukemia
NCT01419496 ·Status: COMPLETED
-
A Phase Ib Study of Panobinostat (LBH589) in Combination With 5-Azacitidine for Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) Patients
NCT01613976 ·Status: COMPLETED ·Phase: PHASE1
-
Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia
NCT01229956 ·Status: COMPLETED
-
Real-World Disease Management and Outcomes in Chronic Myeloid Leukaemia
NCT05893836 ·Status: COMPLETED
-
Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects
NCT06536452 ·Status: RECRUITING
-
Biomarkers in Samples From Patients With B-Cell Acute Lymphoblastic Leukemia
NCT01505699 ·Status: COMPLETED
-
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers
NCT01120457 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Splenic Irradiation in Chronic Lymphatic Leukemia
NCT02020109 ·Status: WITHDRAWN
-
Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia
NCT02879695 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1